Valiant Laboratories Ltd Stock Hits All-Time Low Amidst Continued Downtrend

Recent Market Performance and Price Trends

On 21 Jan 2026, Valiant Laboratories Ltd’s stock price fell by 1.66%, underperforming the Sensex which declined by 0.30% on the same day. The stock is trading just 0.69% above its 52-week low of ₹59.38, signalling a near-record trough in its market valuation. Over the past week, the stock has dropped 9.03%, significantly lagging the Sensex’s 1.73% decline. The one-month performance shows a 12.51% decrease against the Sensex’s 3.52% fall, while the year-to-date return stands at -16.14%, compared to the Sensex’s -3.85%.

Longer-term trends reveal a stark contrast with the broader market. Over the last year, Valiant Laboratories Ltd’s stock has plummeted by 47.18%, whereas the Sensex has appreciated by 8.04%. The company’s three-year, five-year, and ten-year returns remain at zero, highlighting a prolonged period of stagnation, while the Sensex has delivered gains of 35.16%, 65.11%, and 241.95% respectively over these intervals.

Technical Indicators and Moving Averages

Technically, the stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a persistent bearish trend. Despite a brief two-day gain following consecutive declines, the overall momentum remains subdued. The stock’s underperformance relative to its Pharmaceuticals & Biotechnology sector peers by 0.31% on the latest trading day further emphasises its relative weakness.

Fundamental Analysis and Financial Metrics

Valiant Laboratories Ltd’s fundamental profile remains weak, as reflected in its MarketsMOJO Mojo Score of 23.0 and a Mojo Grade of Strong Sell, upgraded from Sell on 17 Nov 2025. The company’s market capitalisation grade is rated 4, indicating a relatively small market cap within its sector.

The company’s operating profits have declined at a compound annual growth rate (CAGR) of -49.92% over the past five years, signalling deteriorating profitability. Its ability to service debt is constrained, with an average EBIT to interest coverage ratio of just 0.65, well below the threshold for comfortable debt servicing.

Return on Equity (ROE) remains subdued, averaging 0.80%, which points to limited profitability generated per unit of shareholders’ funds. The latest reported ROE is 1.6%, accompanied by a price-to-book value ratio of 1, suggesting an expensive valuation relative to its own book value despite the stock’s depressed price levels.

Interestingly, the stock trades at a discount compared to its peers’ average historical valuations, which may reflect market concerns about its financial health and growth prospects. Over the past year, while the stock price has declined by 47.18%, the company’s profits have increased by 150.8%, resulting in a PEG ratio of 0.5. This divergence between profit growth and share price performance highlights a disconnect that investors have yet to reconcile.

Sales and Profitability Trends

Despite the stock’s poor market performance, Valiant Laboratories Ltd has reported positive results for the last three consecutive quarters. Net sales for the latest six-month period stood at ₹93.02 crores, representing a growth rate of 130.48%. Profit after tax (PAT) for the same period was ₹2.02 crores, up 138.48%. These figures indicate operational improvements in revenue and profitability, although these have not translated into share price gains.

The company’s promoter group remains the majority shareholder, maintaining control over strategic decisions and corporate governance.

Comparative Market Context

Valiant Laboratories Ltd’s underperformance is stark when compared to the broader market indices. The BSE500 index has generated a return of 6.44% over the last year, while the stock has delivered a negative return of 47.18%. This divergence highlights the stock’s relative weakness within the Pharmaceuticals & Biotechnology sector and the wider market.

The stock’s persistent decline and trading near all-time lows reflect ongoing valuation pressures and investor caution. The company’s financial metrics, including weak profitability ratios and limited debt servicing capacity, contribute to the subdued market sentiment.

Summary of Key Financial and Market Indicators

To summarise, Valiant Laboratories Ltd’s stock is characterised by:

• Trading near its 52-week low, just 0.69% above the lowest price point


• Underperformance relative to Sensex and sector indices across multiple time frames


• Mojo Score of 23.0 with a Strong Sell grade, reflecting weak fundamentals


• Negative five-year CAGR in operating profits of -49.92%


• Low EBIT to interest coverage ratio of 0.65, indicating limited debt servicing ability


• Subdued average ROE of 0.80%, with a recent figure of 1.6%


• Positive sales and profit growth in the latest six months, though not reflected in share price

These factors collectively illustrate the challenges faced by Valiant Laboratories Ltd in regaining investor confidence and market valuation.

Unlock special upgrade rates for a limited period. Start Saving Now →